more_reports

200 Brain PET Scans, 162 Alzheimer's Drugs: A Diagnostic Push Takes Shape

  ()
Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) signed an LOI tied to a minimum of 200 brain PET scans for an Alzheimer's clinical trial while expanding its NovaScan neuroimaging strategy.
Tags: Life Sciences Tools & DiagnosticsHealthcare Services

Cleantech Co. Wins PFAS Deal, Engineering Pact, Ships Clyra

Research Report
  ()
BioLargo (BLGO:OTCQX) shipped Clyra's first stocking order, signed Aquatech PFAS MOU, and won a US$1.2M engineering contract for a minerals processing facility, according to an Oak Ridge Financial research note
Tags: Life Sciences Tools & DiagnosticsCleantech

Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans

  ()
Keros Therapeutics Inc. (KROS:NASDAQ) lowered research spending & reported funding through 2028 as analysts monitor upcoming trial catalysts for ALS & Muscular Dystrophy drugs.
Tags: Biotechnology / Pharmaceuticals

Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles

Research Report
  ()
Keros Therapeutics (KROS:NASDAQ) disclosed that initiation of its Phase 2 rinvatercept study in Duchenne muscular dystrophy will slip from 2Q26 to 3Q26 due to procedural regulatory delays, according to a Wedbush research note.
Tags: Biotechnology / Pharmaceuticals

New York Digital Health Firm Expands Reach to 116 Million Covered Lives

  ()
DarioHealth Corp. (DRIO:NASDAQ) reported first quarter 2026 results showing sequential revenue growth, lower operating expenses, expanded channel partnerships and a US$127 million commercial pipeline.
Tags: Healthcare Services

Biotech Co. Unveils Scalable AI Voice Biomarker Platform

  ()
MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) CEO says proprietary AI voice analytics could transform impairment screening across zero-tolerance industries.
Tags: Life Sciences Tools & Diagnostics

FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential

Research Report
  ()
D. Boral Capital analyst Jason Kolbert reiterated his rating and price target on Coya Therapeutics Inc. (COYA:NASDAQ) following the company's receipt of FDA Fast Track Designation for COYA 302 in ALS.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Advances AI Detection Breakthrough for Intoxication Safety

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) enhances AI speech analysis tech with cross-language capability, paving the way for major accident-prevention potential.
Tags: Life Sciences Tools & Diagnostics

California Biotech Co. Discovers VOXZOGO Breakthrough, Reports Strong Q1

  ()
BioMarin Pharmaceuticals Inc. (BMRN:NASDAQ) delivered positive long-term achondroplasia data alongside rising revenues, accelerating rare disease portfolio growth.
Tags: Biotechnology / Pharmaceuticals

Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results

  ()
Niagen Bioscience Inc. (NAGE:NASDAQ) reports a 3% increase in total net sales to US$31.5 million for the first quarter. Read why analysts recommend this stock in a rapidly expanding market.
Tags: Biotechnology / Pharmaceuticals

Sublingual Drug Reformulator Expands into Caffeine Market and Gets Capital Injection

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson reviews Aspire Biopharma Holdings, Inc. (ASBP:NASDAQ) in light of its recent news.
Tags: Biotechnology / Pharmaceuticals

CleanTech Company Advances Global PFAS Water Treatment Partnership with Aquatech

  ()
Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) notches multiple wins this week for the distribution of its products worldwide.
Tags: Special SituationsLife Sciences Tools & DiagnosticsTechnology

FDA Rejects Melanoma Drug Again as Analysts Slash Targets and Approval Path Comes Under Fire

  ()
Replimune Group Inc. (REPL:NASDAQ) received a second FDA rejection for RP1 in advanced melanoma, prompting analyst downgrades, price target cuts, and renewed debate over approval standards for cancer therapies.
Tags: Biotechnology / Pharmaceuticals

Oncology Company Given Neutral Rating as Q1/26 Beat Sets Up Catalyst

Research Report
  ()
Wedbush Securities reiterated a Neutral rating on Novocure Ltd. (NVCR:NASDAQ) after the company posted a Q1/26 revenue beat of US$174.1 million, raised FY26 guidance to US$690710 million, and reported encouraging early Optune Pax launch metrics.
Tags: Biotechnology / Pharmaceuticals

Three AI-Driven Cancer Programs Advance Toward Key 2026 Milestones

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) reported 2025 financial results and outlined progress across its kt-5000, kt-3283, and kt-2000 programs, alongside financing, leadership updates, and ongoing AI partnerships.
Tags: Healthcare ServicesBiotechnology / Pharmaceuticals

Oncology Co. Tests Advanced Cancer Treatments, Reports Q1 2026 Financial Results

  ()
Novocure Ltd. (NVCR:NASDAQ) posted 12% revenue growth, strong international patient gains, FDA momentum, and promising pancreatic cancer trial results in 2026.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA

Research Report
  ()
Wedbush Securities downgraded Replimune Group Inc. (NASDAQ:REPL) to NEUTRAL after the FDA issued a second complete response letter for RP1 in PD-1 refractory melanoma.
Tags: Biotechnology / Pharmaceuticals

Biotech Downgraded to Neutral After Second FDA CRL for Reproxalap in Dry Eye Disease

Research Report
  ()
H.C. Wainwright & Co. downgraded Aldeyra Therapeutics Inc. (ALDX:NASDAQ) to Neutral and slashed its price target after the company received a second FDA Complete Response Letter for its Reproxalap NDA in dry eye disease.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Faces Mounting ELEVIDYS Efficacy Risk as Roche Phase 3 Study Threatens US Franchise

Research Report
  ()
H.C. Wainwright analysts argue that Roche's new placebo-controlled Phase 3 study of ELEVIDYS, while aimed at reopening the European market, creates significant downside risk for Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) core U.S. ambulatory business by potentially generating another failed NSAA readout.
Tags: Biotechnology / Pharmaceuticals

Wedbush Sees Denifanstat as Front-Line Acne Therapy with 249% Upside Potential

Research Report
  ()
Wedbush Securities analyst Dr. Yun Zhong reiterated a price target on Sagimet Biosciences (SGMT:NASDAQ), implying roughly 249% upside.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Finds Massive Physiological Screening Breakthrough

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) files patents for novel voice-biomarker intoxication detection, targeting applications in mining and aviation.
Tags: Life Sciences Tools & DiagnosticsArtificial Intelligence